Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Psychiatry
Volume 2015, Article ID 542862, 12 pages
http://dx.doi.org/10.1155/2015/542862
Case Report

Three Patients Needing High Doses of Valproic Acid to Get Therapeutic Concentrations

1Department of Psychiatry, College of Medicine, University of Kentucky, Lexington, KY 40509, USA
2Pharmacy, Eastern State Hospital, Lexington, KY 40511, USA
3Apalachee, Inc., Eastside Psychiatric Hospital, Tallahassee, FL 32308, USA
4Department of Biostatistics, The University of Kansas Medical Center, Kansas City, KS 66160, USA
5University of Kentucky Mental Health Research Center, Eastern State Hospital, Lexington, KY 40511, USA

Received 28 February 2015; Accepted 8 April 2015

Academic Editor: Liliana Dell’Osso

Copyright © 2015 James Jackson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. M. Peterson and M. Naunton, “Valproate: a simple chemical with so much to offer,” Journal of Clinical Pharmacy and Therapeutics, vol. 30, no. 5, pp. 417–421, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. Lexicomp, Drug Information Handbook, Lexi-Comp, Hudson, Ohio, USA, 23rd edition, 2014.
  3. P. N. Patsalos, D. J. Berry, B. F. D. Bourgeois et al., “Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies,” Epilepsia, vol. 49, no. 7, pp. 1239–1276, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. G. D. Anderson, “A mechanistic approach to antiepileptic drug interactions,” Annals of Pharmacotherapy, vol. 32, no. 5, pp. 554–563, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. C. L. DeVane, “Pharmacokinetics, drug interactions, and tolerability of valproate,” Psychopharmacology Bulletin, vol. 37, supplement 2, pp. 25–42, 2003. View at Google Scholar · View at Scopus
  6. J. Fleming and M. Chetty, “Psychotropic drug interactions with valproate,” Clinical Neuropharmacology, vol. 28, no. 2, pp. 96–101, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. T. K. L. Kiang, P. C. Ho, M. R. Anari, V. Tong, F. S. Abbott, and T. K. H. Chang, “Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype,” Toxicological Sciences, vol. 94, no. 2, pp. 261–271, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Nagai, S. Ono, N. Yasui-Furukori, A. Nakamura, K. Mihara, and T. Kondo, “Formulations of valproate alter valproate metabolism: a single oral dose kinetic study,” Therapeutic Drug Monitoring, vol. 31, no. 5, pp. 592–596, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. U. A. Argikar and R. P. Remmel, “Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10,” Drug Metabolism and Disposition, vol. 37, no. 1, pp. 229–236, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. J. E. Fisher, H. Nau, and W. Löscher, “Alterations in the renal excretion of valproate and its metabolites after chronic treatment,” Epilepsia, vol. 32, no. 1, pp. 146–150, 1991. View at Publisher · View at Google Scholar · View at Scopus
  11. W. D. Hooper, M. E. Franklin, P. Glue et al., “Effect of felbamate on valproic acid disposition in healthy volunteers: Inhibition of beta-oxidation,” Epilepsia, vol. 37, no. 1, pp. 91–97, 1996. View at Publisher · View at Google Scholar · View at Scopus
  12. G. D. Anderson, M. K. Yau, B. E. Gidal et al., “Bidirectional interaction of valproate and lamotrigine in healthy subjects,” Clinical Pharmacology & Therapeutics, vol. 60, no. 2, pp. 145–156, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. D. B. McLaughlin, J. A. Andrews, W. D. Hooper, G. R. Canned, M. J. Eadie, and R. G. Dickinson, “Apparent autoinduction of valproate β-oxidation in humans,” British Journal of Clinical Pharmacology, vol. 49, no. 5, pp. 409–415, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Cerveny, L. Svecova, E. Anzenbacherova et al., “Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways,” Drug Metabolism and Disposition, vol. 35, no. 7, pp. 1032–1041, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. F. A. de Jong, J. M. van der Bol, R. H. J. Mathijssen et al., “Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity,” Cancer Biology & Therapy, vol. 6, no. 9, pp. 1368–1374, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Citrome, R. Josiassen, N. Bark, D. E. Salazar, and S. Mallikaarjun, “Pharmacokinetics of aripiprazole and concomitant lithium and valproate,” Journal of Clinical Pharmacology, vol. 45, no. 1, pp. 89–93, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Bergemann, K. R. Kress, F. Abu-Tair, A. Frick, and J. Kopitz, “Valproate lowers plasma concentration of olanzapine,” Journal of Clinical Psychopharmacology, vol. 26, no. 4, pp. 432–434, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Haslemo, K. Olsen, H. Lunde, and E. Molden, “Valproic acid significantly lowers serum concentrations of olanzapine-an interaction effect comparable with smoking,” Therapeutic Drug Monitoring, vol. 34, no. 5, pp. 512–517, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Botts, F. J. Diaz, V. Santoro et al., “Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 6, pp. 1453–1458, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Spina, C. D'Arrigo, V. Santoro et al., “Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder,” Therapeutic Drug Monitoring, vol. 31, no. 6, pp. 758–763, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Finley and D. Warner, “Potential impact of valproic acid therapy on clozapine disposition,” Biological Psychiatry, vol. 36, no. 7, pp. 487–488, 1994. View at Publisher · View at Google Scholar · View at Scopus
  22. L. P. Longo and C. Salzman, “Valproic acid effects on serum concentrations of clozapine and norclozapine,” The American Journal of Psychiatry, vol. 152, no. 4, p. 650, 1995. View at Google Scholar · View at Scopus
  23. A. Riesselman, B. Strobl, A. T. Cooley, and J. de Leon, “A case report that suggested that aspirin's effects on valproic acid metabolism may contribute to valproic acid's inducer effects on clozapine metabolism,” Journal of Clinical Psychopharmacology, vol. 33, no. 6, pp. 812–814, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. F. J. Diaz, V. Santoro, E. Spina et al., “Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables,” Pharmacopsychiatry, vol. 41, no. 3, pp. 81–91, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. F. J. Diaz, C. B. Eap, N. Ansermot, S. Crettol, E. Spina, and J. De Leon, “Can valproic acid be an inducer of clozapine metabolism?” Pharmacopsychiatry, vol. 47, no. 3, pp. 89–96, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Vrzal, A. Doricakova, A. Novotna et al., “Valproic acid augments vitamin D receptor-mediated induction of CYP24 by vitamin D3: a possible cause of valproic acid-induced osteomalacia?” Toxicology Letters, vol. 200, no. 3, pp. 146–153, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. J. de Leon, E. Spina, and F. J. Diaz, “Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies,” Therapeutic Drug Monitoring, vol. 35, no. 1, pp. 30–47, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Spina and J. de Leon, “Clinical applications of CYP genotyping in psychiatry,” Journal of Neural Transmission, vol. 122, no. 1, pp. 5–28, 2015. View at Publisher · View at Google Scholar
  29. J. de Leon, J. L. Kiesel, M. W. Fleming, and B. Strobl, “Valproic acid toxicity associated with low dose of aspirin and low total valproic acid levels: a case report,” Journal of Clinical Psychopharmacology, vol. 29, no. 5, pp. 509–511, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Fernández-Pérez, J. M. Álvarez-Dobaño, J. Suárez-Antelo et al., “Eosinophilic pleural effusion associated with the addition of sodium valproate,” Journal of Clinical Psychopharmacology, vol. 29, no. 3, pp. 310–311, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. K. T. Brady, S. C. Sonne, R. Anton, and J. C. Ballenger, “Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study,” Journal of Clinical Psychiatry, vol. 56, no. 3, pp. 118–121, 1995. View at Google Scholar · View at Scopus
  32. J. R. Horn, P. D. Hansten, and L. N. Chan, “Proposal for a new tool to evaluate drug interaction cases,” Annals of Pharmacotherapy, vol. 41, no. 4, pp. 674–680, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Coffey, S. Botts, and J. de Leon, “Dosing differences between valproic acid concentrate and divalproex sodium: a case report,” The Journal of Clinical Psychiatry, vol. 65, no. 5, pp. 724–725, 2004. View at Google Scholar · View at Scopus
  34. J. de Leon and F. J. Diaz, “Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 27, no. 6, pp. 1059–1063, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. J. D. Sherr and D. L. Kelly, “Substitution of immediate-release valproic acid for divalproex sodium for adult psychiatric inpatients,” Psychiatric Services, vol. 49, no. 10, pp. 1355–1357, 1998. View at Publisher · View at Google Scholar · View at Scopus